News >

Daratumumab-Based 4-Drug Induction Regimens Improve Outcomes in Myeloma

Kristi Rosa
Published: Monday, Dec 23, 2019

Ajay K. Nooka, MD, MPH, FACP, an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine

Ajay K. Nooka, MD, MPH, FACP

Newer induction regimens containing daratumumab (Darzalex) are showing impressive depths of response without significant added toxicity in patients with multiple myeloma, regardless of transplant eligibility, according to Ajay K. Nooka, MD, MPH, FACP.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication